Reportstack

Allergan Limited - Product Pipeline Review - 2013

 

Naperville, IL -- (SBWIRE) -- 07/08/2013 -- Reportstack, provider of premium market research reports announces the addition of Allergan Limited - Product Pipeline Review - 2013 market report to its offering
Allergan Limited - Product Pipeline Review - 2013

Summary

Global Market Direct's pharmaceuticals report, Allergan Limited - Product Pipeline Review - 2013 provides data on the Allergan Limited's research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct's proprietary databases, Allergan Limited's corporate website, SEC filings, investor presentations and featured press releases, both from Allergan Limited and industry-specific third party sources, put together by Global Markets Direct's team.

Scope

- Allergan Limited - Brief Allergan Limited overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Allergan Limited human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Allergan Limited with complete description of the product's developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Allergan Limited's pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Allergan Limited's strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Allergan Limited in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Allergan Limited's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Allergan Limited.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Allergan Limited and identify potential opportunities in those areas.

To view the table of contents for this market research report please visit
http://www.reportstack.com/product/116735/allergan-limited-product-pipeline-review-2013.html